Showing results (51-60 of 199) with videos related to

Sort By:
Pageof 20
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|August 3, 2024
New challenges of advanced therapiesJuan Eduardo Megías-Vericat, Ana Bonora-Centelles A, Tomás Palanques-Pastor, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|August 3, 2024
[Translated article] New challenges in advanced therapiesJuan Eduardo Megías-Vericat, Ana Bonora-Centelles A, Tomás Palanques-Pastor, et al.
Transfusion Medicine Reviews|October 9, 2024
Single-Unit Transfusion Policy in Autologous Hematopoietic Stem Cell Transplantation: Less is Not WorseJavier Marco-Ayala, Pedro Asensi Cantó, Marina Suarez, et al.
Hematology (Amsterdam, Netherlands)|February 21, 2023
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS studyRafael Ríos-Tamayo, Juan Alfons Soler, Ricarda García-Sánchez, et al.
Leukemia & Lymphoma|September 13, 2006
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantationNoemí Puig, Javier de la Rubia, María J Remigia, et al.
Transplantation and Cellular Therapy|January 16, 2023
Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell TransplantationJavier Marco-Ayala, Jaime Sanz, Inés Gómez-Seguí, et al.
Leukemia Research|August 23, 2002
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignanciesJavier de la Rubia, Ana Regadera, Guillermo Martín, et al.
British Journal of Haematology|May 15, 2015
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosisMaria T Cibeira, Albert Oriol, Juan J Lahuerta, et al.
Blood Advances|April 21, 2021
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysisFlora Peyvandi, Spero Cataland, Marie Scully, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2019
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES studyPaul Knoebl, Spero Cataland, Flora Peyvandi, et al.
Pageof 20